Rosetta Genomics, Moffitt Cancer Center to Collaborate on microRNA Cancer Diagnostics | GenomeWeb

NEW YORK (GenomeWeb) – Molecular diagnostics firm Rosetta Genomics announced today that it has formed a three-year collaboration with the Moffitt Cancer Center to discover, develop, and commercialize a range of microRNA-based cancer tests.

The alliance combines Rosetta's expertise in developing and commercializing miRNA diagnostics with Moffitt's network of medical oncologists and pathologists, and will focus specifically on areas of unmet medical need.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.